Chemotherapy for Potentially Resectable Locally Advanced Esophagogastric Junction Carcinoma
- Conditions
- Esophagogastric Junction Cancer
- Registration Number
- NCT03211377
- Lead Sponsor
- Anyang Tumor Hospital
- Brief Summary
This is a non-interventional study to observe the safety and efficiency of chemotherapy for potentially resectable locally advanced esophagogastric junction
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
- Histologically or cytological proved locally advanced esophagogastric junction cancer
- ECOG performance status ≦2
- Stage IIa-IIIc
- No distant metastasis (M0)
- Sign in Informed Consent Form
Exclusion Criteria
- History of hypersensitivity to fluoropyrimidines, Tegafur，Gimeracil and Oteracil Potassium Capsules , capecitabine, oxaliplatin or the ingredients of this product
- Pregnancy or lactation women,
- Inadequate hematopoietic function： WBC≦3,500/mm3; ANC≦1,500/mm3; Platelet≦80,000/mm3
- Inadequate organ function which is defined as below:
Total bilirubin >2 pper limit of normal range (ULN); ALT / AST > 2.5 upper limit of normal range (ULN); serum creatinine > 1.5 mg/dL, and Ccr > 60 ml/min (estimated by Cockcroft-Gault formulation);
- Symptomatic peripheral neuropathy
- Receiving a concomitant treatment with other fluoropyrimidines
- Fluoropyrimidines (DPD) congenital absence
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method disease free survival(DFS) up to 3 years time from surgery to disease recurrence or death
- Secondary Outcome Measures
Name Time Method Adverse events(AE) through study completion, up to 1 year Investigators graded all adverse events and toxic effects according to the National Cancer Institute's Common Toxicity Criteria, version 4.03.
Overall survival (OS) up to 5 years time to death
Trial Locations
- Locations (1)
Department of science and education
🇨🇳Anyang, Henan, China